CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 560 enrolled
Drug / intervention
G2-TR intraocular implant containing travoprost +1 morecombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03868124
NCT03868124Phase 3Completed
CompareCT.gov

Prospective, Randomized Phase III Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%

Glaukos Corporation·interventional·Posted Mar 8, 2019·Updated Nov 29, 2024

In Brief

A Phase 3 clinical trial evaluating G2-TR intraocular implant containing travoprost and Sham surgery + active-comparator eye drops for Glaucoma, Open-Angle and Ocular Hypertension. Completed, enrolled 560 participants across 1 site.

Detailed Summary

Phase III study to compare the safety and efficacy of intraocular implants containing Travoprost at two different elution rates versus Timolol Maleate Ophthalmic Solution, 0.5% (Timolol) in reducing elevated intraocular pressure in subjects with open angle glaucoma (OAG) or ocular hypertension (OHT)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open-Angle, Ocular Hypertension
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedMar 8, 2019
Enrollment StartSep 17, 2018
Primary CompletionJun 10, 2022
Study CompletionJun 19, 2024
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 7.3 years ago

Interventions

G2-TR intraocular implant containing travoprostcombination

Provided in Arm/Group descriptions

Sham surgery + active-comparator eye dropsdrug

Sham surgery plus postoperative active-comparator eye drops (Timolol Maleate ophthalmic solution, 0.5%)